On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences.